UNSPSC 51112203: Doxorubicin/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN200. This VA Drug Class (AN200) classifies this compound as belonging to the group ANTINEOPLASTIC ANTIBIOTICS.

UNSPSC 51112203 Doxorubicin/sodium chloride is a Commodity code nominally identifying a specific pharmaceutical product, but the most recent state and local procurement activity under this code does not involve direct procurement of the drug itself. Instead, the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor capabilities and market intelligence regarding implementation of a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks information from vendors about their capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, bypassing existing arrangements with pharmacy benefit managers, group purchasing organizations, and wholesalers. Key vendor qualifications solicited include experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The procurement mechanism is exploratory in nature — designed to gather market intelligence and inform future procurement strategy rather than to solicit bids for immediate product delivery.

The sole recent opportunity under this code originates from a state health agency (Texas HHS Commission) and signals a shift in how state and local governments may source pharmaceutical products going forward. The RFI, posted April 3, 2026 with a same-day response deadline, represents preliminary market research before formal RFP issuance. No award value, budget range, set-aside designations, or specific response requirements are defined, reflecting the information-gathering phase of the procurement. This activity suggests that state pharmaceutical procurement strategy is moving toward direct manufacturer relationships and alternative pricing models; vendors pursuing state and local pharmacy contracts should monitor Texas HHS for follow-on formal solicitations as the agency develops procurement specifications and implementation timelines based on RFI responses.